vTv Therapeutics (NASDAQ:VTVT) Stock Price Passes Above Fifty Day Moving Average of $18.21

Shares of vTv Therapeutics Inc. (NASDAQ:VTVT) passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $18.21 and traded as high as $24.96. vTv Therapeutics shares last traded at $24.74, with a volume of 3,423 shares trading hands.

Analyst Ratings Changes

Separately, StockNews.com raised shares of vTv Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, March 14th.

vTv Therapeutics Price Performance

The stock has a market cap of $74.47 million, a P/E ratio of -2.46 and a beta of 0.56. The firm’s fifty day moving average price is $18.21 and its two-hundred day moving average price is $14.46.

vTv Therapeutics (NASDAQ:VTVT) last posted its earnings results on Wednesday, March 13th. The biotechnology company reported ($1.67) EPS for the quarter.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of VTVT. Pathstone Family Office LLC bought a new stake in vTv Therapeutics during the third quarter valued at approximately $116,000. State Street Corp raised its position in shares of vTv Therapeutics by 268.7% during the 2nd quarter. State Street Corp now owns 206,145 shares of the biotechnology company’s stock valued at $155,000 after buying an additional 150,228 shares in the last quarter. Prudential Financial Inc. bought a new stake in shares of vTv Therapeutics during the 2nd quarter worth $30,000. Finally, Millennium Management LLC grew its position in vTv Therapeutics by 12.0% in the second quarter. Millennium Management LLC now owns 138,683 shares of the biotechnology company’s stock worth $104,000 after acquiring an additional 14,845 shares in the last quarter. 17.51% of the stock is currently owned by institutional investors.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes that is in Phase III clinical trial; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases, psoriasis, COPD, and Atopic Dermatitis that is in Phase III clinical trial.